Here We Go: NIH Begins Testing Phase I Clinical Trial of Universal Flu Vaccine

0
128

by Jim Hoft, The Gateway Pundit:

The National Institutes of Health (NIH) announced on Tuesday that they had started conducting a phase 1 clinical trial of universal flu vaccination on healthy adult volunteers at the NIH Clinical Center in Bethesda, Maryland.

NIH is testing if this new flu vaccine is safe and if it creates an immune response.

TRUTH LIVES on at https://sgtreport.tv/

The National Institute of Allergy and Infectious Diseases ((NIAID) researchers created the potential vaccine known as BPL-1357. NIAID researcher Matthew J. Memoli, M.D. is in charge of the single-site experiment, which is open to 100 participants ages 18 to 55, according to the press release.

“Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools,” said NIAID Director Anthony S. Fauci. “The scientific community is making progress on this pressing global health priority. The BPL-1357 candidate influenza vaccine being tested in this clinical trial performed very well in pre-clinical studies and we look forward to learning how it performs in people.”

BPL-1357 is a whole-virus vaccine composed of four strains of non-infectious, chemically inactivated avian flu virus with minimal pathogenicity. A study in mice led by NIAID investigator Jeffery K. Taubenberger, M.D., Ph.D., and published online as a pre-print found that all mice who received two doses of BPL-1357 vaccine delivered either intramuscularly or intranasally survived later exposure to lethal doses of each of six different influenza virus strains, including subtypes not included in the vaccine.

Read More @ TheGatewayPundit.com